INCY News and Press, Incyte Corporation From 04/02/20

Cancer and a viral infections wouldn't seem to have much in common, but Incyte (NASDAQ: INCY) is testing its blood cancer drug Jakafi in patients with COVID-19 , the disease caused by the new coronavirus. The connection is that Jakafi helps patients with a blood cancers by inhibiting immun...

- Incyte also intends to launch an Expanded Access Program in the United States to allow eligible patients with COVID-19 associated cytokine storm to receive ruxolitinib - Incyte has an ample commercial and clinical supply of ruxolitinib in the U.S. and is increasing manufacturing effo...

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Strong Buy rating and $86 (221% upside) price target at Raymond James. More news on: Apellis Pharmaceuticals, Inc., BioXcel Therapeutics, Inc., Eidos Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

As the health crisis spirals into a financial one, the liquidation and panic selling have indiscriminately hit sectors across the board. The biotechs were no exception, with the S&P Biotech ETF ( XBI ) plummeting -20% on the year in tandem with the S&P 500 (SPY). Source: WingCapital...

Compugen (NASDAQ: CGEN ) initiated with Buy rating and $16 (156% upside) price target at SunTrust. Shares up  9%  premarket. More news on: Compugen Ltd., Incyte Corporation, NextCure, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Investor conference call and webcast scheduled for Monday, April 6, 2020 at 8:00 a.m. EDT Incyte (Nasdaq:INCY) today announced that data from the Phase 3 TRuE-AD program evaluating ruxolitinib cream for the treatment of patients with mild-to-moderate atopic dermatitis have been accepte...

Eli Lilly (NYSE: LLY ) and Incyte (NASDAQ: INCY ) announces that the FDA has granted Breakthrough Therapy designation (BTD) to baricitinib for the treatment of alopecia areata (AA), an autoimmune disorder that can cause unpredictable hair loss on the scalp, face and other areas of the body...

INDIANAPOLIS , March 16, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to baricitinib for the treatment of alopecia areata (AA)...

Today, we will see why Kadmon Holdings ( KDMN ) is an attractive pick in March 2020. Company overview Founded in 2009, Kadmon Holdings went public in 2016. The company is a late-stage biopharmaceutical company focused on the development and commercialization of small molecule therapies a...

Introduction Syros ( SYRS ) is a biopharmaceutical company focused on developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases. Its leading drug is SY-1425, a selective retinoic acid receptor alpha agonist, or RARα ago...